Scarica l'app Stockscreener
0.00
100.00%
-0.7206
Dopo l'orario di chiusura:
.72
0.72
+
Precedente Chiudi:
$0.7206
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$25.21M
Reddito:
$1.13M
Utile/perdita netta:
$-20.74M
Rapporto P/E:
0.00
EPS:
-0.88
Flusso di cassa netto:
$-18.37M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$1.6199
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Nome
Cyclo Therapeutics Inc
Settore
Telefono
386-418-8060
Indirizzo
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Confronta CYTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTH
Cyclo Therapeutics Inc
|
0.00 | 25.21M | 1.13M | -20.74M | -18.37M | -0.88 |
|
ZTS
Zoetis Inc
|
157.44 | 68.46B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.32 | 47.30B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.70 | 45.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.19 | 17.90B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
294.60 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Cyclo Therapeutics Inc Borsa (CYTH) Ultime notizie
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Rafael Holdings Secures Future: $25M Rights Offering Powers Critical Phase 3 Drug Launch Plans - Stock Titan
Cyclo Therapeutics (NASDAQ:CYTH) and Genfit (NASDAQ:GNFT) Financial Comparison - Defense World
Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - marketscreener.com
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - The Manila Times
Rafael Holdings Announces Leadership Transition Following Merger with Cyclo Therapeutics and Full Enrollment of TransportNPC™ Phase 3 Trial for Niemann-Pick Disease Treatment - Nasdaq
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces - Bluefield Daily Telegraph
Rafael Holdings Pivots to Breakthrough Rare Disease Drug Development as Leadership Changes - Stock Titan
Contrasting BioNTech (NASDAQ:BNTX) and Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Rafael Holdings finalizes merger with Cyclo Therapeutics By Investing.com - Investing.com South Africa
Rafael Closes Merger With Cyclo Therapeutics - MarketScreener
Rafael Holdings and Cyclo Therapeutics Merge - citybiz
Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals - MarketScreener
Cyclo Therapeutics Merges with Rafael Holdings - TipRanks
Rafael Holdings Completes Merger with Cyclo Therapeutics - TipRanks
Rafael Holdings finalizes merger with Cyclo Therapeutics - Investing.com
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals - GlobeNewswire
Major Pharma Merger: Rafael Holdings Gains Phase 3 Rare Disease Asset in Strategic Deal - Stock Titan
Rafael Holdings secures shareholder nod for Cyclo Therapeutics merger By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Rafael Holdings secures shareholder nod for Cyclo Therapeutics merger - Investing.com
Cyclo Therapeutics shareholders approve merger with Rafael Holdings By Investing.com - Investing.com South Africa
Cyclo Therapeutics shareholders approve merger with Rafael Holdings - Investing.com
WILLIAM SHANAHAN Obituary (2025)New York, NYNew York Times - Legacy.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
March Madness: Flutter Stock Is a Solid Bet on Sustained Growth - The Globe and Mail
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office - Business Wire
Q4 Earnings Highlights: Apogee (NASDAQ:APOG) Vs The Rest Of The Commercial Building Products Stocks - The Globe and Mail
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL) - Business Wire
CYCLO THERAPEUTICS Earnings Preview: Recent $CYTH Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rafael Holdings Inc Reports Q2 2025 Earnings: EPS at -$0.19, Str - GuruFocus.com
Rafael Holdings, Inc. SEC 10-Q Report - TradingView
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results - The Manila Times
Rafael Holdings, Inc. Reports Financial Results and Anticipates Closure of Merger with Cyclo Therapeutics in Q3 - Nasdaq
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results - GlobeNewswire Inc.
Cyclo Therapeutics (CYTH) to Release Quarterly Earnings on Monday - Defense World
Cyclo Therapeutics secures $2.5 million in funding By Investing.com - Investing.com Australia
Is Cyclo Therapeutics, Inc. (CYTH) the Best Micro Cap Stock to Buy Now? - Insider Monkey
10 Best Micro Cap Stocks to Buy Now - Insider Monkey
Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings - Marketscreener.com
Cyclo Therapeutics secures $2.5 million in funding - Investing.com India
Emerging Market ETFs: A Shield Against Trump’s Tariff Threats? - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLUE, VOXX, CARA, CYTH on Behalf of Shareholders - The Malaysian Reserve
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc.CYTH - Business Wire
Emera Inc (EMA:CA) Stock Analysis: Q4 2024 Earnings & Forecast - The Globe and Mail
Cyclo Therapeutics extends merger agreement with Rafael Holdings - MSN
Cyclo Therapeutics Inc Azioni (CYTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):